National and Kapodistrian University of Athens
Η εμπλοκή των ανοσιακών παραγόντων στην αιτιοπαθογένεια και στην θεραπευτική ανταπόκριση σε ασθενείς με ψύχωση
Abstract
dc:descriptionSchizophrenia is a multifaceted and chronic mental disorder characterized by a constellation of symptoms affecting an individual's cognition, emotions, perception, social functioning and behaviors. The exact cause of schizophrenia remains elusive, but it is believed to result from a complex interplay of genetic, environmental, and neurobiological factors. Research suggests abnormalities in brain structure and neurotransmitter imbalances, particularly involving dopamine and glutamate, may contribute to the onset and progression of the disorder. In addition, evidence suggests that individuals with schizophrenia often exhibit alterations in immune function, including increased levels of pro-inflammatory cytokines and immune activation markers. Studies have revealed higher levels of inflammatory molecules, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and C-reactive protein (CRP), in the blood and/or cerebrospinal fluid of some individuals with schizophrenia compared to healthy individuals. In turn, these alterations in immune function might contribute to neuronal damage, oxidative stress, and alterations in synaptic plasticity, neural circuits and neurotransmitter systems, all of which could influence the onset or progression of schizophrenia. In this context, evidence suggests that inflammation-induced alterations in the physiological functioning of the kynurenine pathway, a critical metabolic pathway responsible for the breakdown of tryptophan and regulator of immune responses, neurotransmission and inflammation, may contribute to the schizophrenic symptomatology, disease severity and response to treatment. Understanding the molecular underpinnings of schizophrenia is essential as there is currently no cure, emphasizing the need to advance our knowledge for the development of innovative diagnostic and clinical approaches. This thesis aims to elucidate the link between systemic inflammation and the kynurenine pathway in medication-naïve patients during first psychotic episodes. Specifically, we divided individuals into two groups to examine the relationship between inflammation and psychotic disorders. The first group comprised 128 patients who had recently experienced their first psychotic episode and remained medication-free, with complete data collected from 100 individuals. Patients with active inflammation or organic psychosis were excluded. The second group consisted of 81 carefully screened healthy individuals. Data on personal and family history were collected to rule out psychopathology. Blood collection occurred twice: during the initial psychotic episode and one month post-treatment. Samples were processed and stored for analysis. Parameters of inflammation (CRP) were assessed using nephelometry, while immunological analyses focused on IL-1β, TNF-α, and IL-10 measured by ELISA. We also measured by ELISA key enzymes and metabolites of trypthophan metabolism such as IDO, TDO KYNA and QUINA. Furthermore, we examined the levels of the neurotrophic factor BDNF. Using regression models and advanced statistical tools, all the aforementioned biomarkers were associated with symptom severity and response to treatment. The first psychotic episode is accompanied by elevated pro-inflammatory cytokines as indicated by serum levels of IL-1β and TNF-α. Οf note, levels of the anti-inflammatory cytokine IL-10 did not differ significantly between patients and healthy controls. Together, the findings of the current research suggest that an increased inflammatory response occurs at the onset of a psychotic episode. We also observed heightened activation of the Kynurenine Pathway. This statistically significant observation is more pronounced in patients diagnosed with psychotic disorders other than schizophrenia. Notably, the neurotrophic factor BDNF appears diminished from the early stages of psychosis, potentially relating to brain neuroplasticity. Comparing patients before and after one month of antipsychotic treatment revealed reduced levels of pro-inflammatory cytokines, indicating that antipsychotic medication influences the immune profile. Importantly, however, these decreases did not reach levels observed in healthy controls. The concentration of the anti-inflammatory cytokine IL-10 also decreased but, unlike the pro-inflammatory cytokines, did not reach statistical significance. Correlations between biomarker levels and symptomatology sub-scores based on the PANSS scale before and after treatment suggest that patients with higher IL-1β levels at admission displayed milder psychopathology. This was notably evident in patients diagnosed with psychotic disorders other than schizophrenia. Increased KYNA levels upon diagnosis in schizophrenia patients were associated with more negative symptoms post-treatment. Regression models showed that patients with higher KYNA levels at admission exhibited poorer response to treatment. Mediation analyses suggested that the relationship between KYNA levels and treatment non-response was mediated through negative symptoms. Activated KYNA increased negative symptoms while reducing treatment response. The implications of this research are critical since investigating KYNA's potential as a prognostic biomarker for treatment non-response in early psychosis could significantly advance clinical interventions. Future investigations could involve longitudinal studies beyond one month of treatment adherence to further elucidate the trajectory of these biomarkers, predominantly KYNA. Additionally, studying the influence of distinct pharmacotherapies on patients' immune and metabolic profiles is crucial for delineating more personalized and efficient interventions. Finally, future research could group patients according to serum KYNA levels in order to elucidate the range at which KYNA demonstrates neuroprotective effects against damage caused by neurotoxic QUINA, versus the specific levels at which elevated KYNA contributes to pathological changes in neurotransmission. It is possible that the current unclear - and often contrasting in the bibliography - role of KYNA in psychosis depends to some extent on the absence of such threshold.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Foteli, Stefania-Panagiota
- Φωτέλη, Στεφανία-Παναγιώτα
Subjects
dc:subject × 18- Πρώτο ψυχωτικό επεισόδιο
- Σχιζοφρένεια
- Μονοπάτι κυνουρενίνης
- Κυνουρενικό οξύ
- Ανοσιακό σύστημα
- Κυττοκίνες
- Psychosis
- Schizophrenia
- Kynourenic acid
- Tryptophan metabolism
- Positive and negative symptons scale (PANSS)
- Indoleamine 2,3-dioxygenase
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ψυχιατρική και Ψυχική υγεία
- Clinical Medicine
- Medical and Health Sciences
- Psychiatry and Mental Health
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/57791